VCAN Canonical Splice Site Mutation is Associated With Vitreoretinal Degeneration and Disrupts an MMP Proteolytic Site

Peter H. Tang,1,2 Gabriel Velez,1,5 Stephen H. Tsang,4 Alexander G. Bassuk,5 and Vinit B. Mahajan1,2

1Byers Eye Institute, Omics Laboratory, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California, United States
2Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States
3Medical Scientist Training Program, University of Iowa, Iowa City, Iowa, United States
4Bernard and Shirlee Brown Glaucoma Laboratory, Department of Pathology and Cell Biology, Department of Ophthalmology, College of Physicians and Surgeons, Columbia University, New York, New York, United States
5Department of Pediatrics, University of Iowa, Iowa City, Iowa, United States

Correspondence: Vinit B. Mahajan, Omics Laboratory, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA 94304, USA; vinit.mahajan@stanford.com.

Submitted: August 31, 2018
Accepted: November 29, 2018
Citation: Tang PH, Velez G, Tsang SH, Bassuk AG, Mahajan VB. VCAN canonical splice site mutation is associated with vitreoretinal degeneration and disrupts an MMP proteolytic site. Invest Ophthalmol Vis Sci. 2019;60:282–293. https://doi.org/10.1167/iovs.18-25624

Erosive vitreoretinopathy (EVR) and Wagner disease are classically described as separate entities, but recent genetic studies revealed both are due to autosomal dominant mutations in the VCAN gene (Online Mendelian Inheritance in Man #118661).1–4 This gene is localized to chromosome 5q13-q14 and encodes for an extracellular matrix (ECM) chondroitin sulfate proteoglycan called versican, the exact role of which is not well understood.5,6 Both Wagner disease and EVR are extremely rare, with 14 pedigrees (with >250 individuals) having been described.2–11 Patients with Wagner disease can exhibit vitreous syneresis, an optically empty vitreous, equatorial avascular vitreous veins, mild to moderate myopia, cortical cataracts, abnormal retinal vessel architecture (inverted papilla), ectopic fovea, perivascular pigmentation and sheathing, spontaneous uveitis; however, the mechanism is not well understood.5,6,15 Thus, it may be helpful to view both conditions as existing on a spectrum ranging from mild (Wagner disease) to severe (EVR) phenotypes. In the current study, we have termed this collective spectrum of clinical findings as Versican Vitreoretinopathy (VVR).

Turnover of versican through proteolytic processing appears to play an important role in the physiologic structure of tissues, including the vitreous. Proteolytic cleavage of versican by matrix metalloproteinases (MMPs) and A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) proteases16–18 is a critical step in the process of ECM modeling, particularly during embryonic development. Early on, versican-bound hyaluronic acid forms a loose hydrated matrix that allows for rapid modeling and morphogenesis.19 Versican cleavage facilitates the compaction and sculpting of the ECM in versican-rich tissues.19 Physiologic versican cleavage is not just degradative—proteolytic processing is highly regulated and can result in the formation of bioactive cleavage products. For
example, ADAMTS-mediated processing of versican results in the formation of a 49-kDa functional product, termed versikine, which facilitates apoptosis in coordination with ECM turnover. It is unclear whether additional bioactive fragments are generated. Although the mechanisms for versican processing in the eye are poorly understood, it is hypothesized that dysregulation of these pathways may result in pathologic matrix modeling in the vitreous. The role of versican in eye development is further supported by changes in VCAN protein expression in the developing mouse retina and optic nerve, although its significance remains to be delineated. Furthermore, the Cspg2/Vcan gene was identified as a Pax6 transcriptional target in the developing mouse lens. In addition to facilitating organization of the vitreous gel, the normal hyaluronan network may serve to sequester proteins in the vitreous. Abnormal matrix modeling could potentially release growth factors and proteins that can impact retinal function. A parallel can be drawn to Marfan syndrome, where mutations in the gene encoding fibrillin-1 (FBLN-1) disrupt its ability to sequester TGFβ, leading to a dysregulated TGFβ signal transduction that causes the clinical manifestations, such as RD. In this report, we further elucidate the characteristics of VVR by describing its clinical and histopathologic phenotype, confirming the VCAN c.4004-2A>G mutation in a pedigree of northern European ancestry, and revealing the functional effect of the gene mutation on its protein structure. Finally, using network analysis of protein–protein interactions in the vitreous proteome, we link versican protein effectors to the VVR clinical phenotype.

**METHODS**

**Study Approval**

The study was approved by the institutional review boards at respective universities and adheres to the tenets set forth in the Declaration of Helsinki. Informed consent was obtained from study participants. A chart review of clinical exams was performed.
DNA Sequencing

DNA sequencing and analysis was performed as previously described. Briefly, genomic DNA from patients was isolated from peripheral blood lymphocytes per standard methods. The entire sequence of VCAN (15 exons) was amplified by PCR using pairs of primers that were designed based on the published consensus sequences. Direct sequencing of the PCR-amplified products was analyzed by the Genwize Company (South Plainfield, NJ, USA).

Histologic Analysis

The enucleated eye was fixed in 4% paraformaldehyde solution for 24 hours, washed with PBS, dehydrated using a series of increasing ethanol solution and xylene, embedded in paraffin, sectioned, and mounted on silane-coated slides. Deparaffinized sections were stained with hematoxylin-eosin. Sections were then mounted with cover slip and underwent microscopic analysis and image acquisition.

Cleavage Site Prediction

Proteolytic cleavage sites were predicted with CleavPredict software (Sanford Burnham Medical Research Institute, La Jolla, CA, USA) on the V0 versican primary sequence (NP_004376.2) using default parameters. The analysis returned 28 putative cleavage sites in the VCAN GAG chain (residues 1336–3089). Putative cleavage sites were organized by their respective position weighted matrix (PWM) score calculated by CleavPredict. These sites were further filtered by matching their sequence to the classical gelatinase (MMP-2 and MMP-9) substrate recognition motif, which preferentially contains a leucine or methionine in the P1’ position. This filtering returned 13 putative MMP-2 sites, among which was VCAN p.1335-1344 (PWM score = 2.38). Results of this analysis are summarized in Supplementary Table S1.

Docking Calculations

Docking calculations were performed using the limited structure of VCAN p.1335-1344 in AutoDock VINA with a three-dimensional interaction grid of 96Å × 96Å × 96Å around the human MMP-2 catalytic domain structure (PDB: 1QIB). Partial charges were added to the grid using the AMBER05 parameter set. A total of 25 runs were completed generating multiple clusters of receptor-ligand conformations. Binding energies for each cluster were calculated using the equation in VINA: ΔGbind = RTlnKbind. PyMOL generated all structural images.

MMP Proteolysis Assay

Purified recombinant human pro-MMP-2 (AnaSpec, Fremont, CA, USA) was activated by incubation with 1 mM 4-amino-phenylmercuric acetate (APMA) in a buffer containing 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 5 mM CaCl2, 1 mM ZnCl2, 0.05% Brij35, and 1 mg/mL BSA at 37°C for 1 hour. Proteolytic activity was measured by cleavage of fluorescence resonance energy transfer (FRET)-tagged peptide substrates (Supplementary Table S2; AnaSpec). All FRET peptides contained 5-FAM/QXL dye/quencher pairs. Activated MMP-2 (50 ng per reaction) was incubated with peptide substrate (20 μM) at 37°C for 1 hour. Proteolytic activity was measured as change in raw fluorescence units (ΔRFU; λexc = 490, λem = 520 nm) at 2-minute intervals on a fluorimetric plate reader (Tecan Spark Männedorf, Switzerland). The concentration of 5-FAM released during the experiment was calculated based on a fluorescence standard curve of 5-FAM-PL concentrations (2 nM to 5 μM). VCAN p.1335-1347 hydrolysis by the recombinant human MMP-9 catalytic domain (residues 112–445) was tested using the same conditions. Kinetic parameters were calculated by direct fitting to the Michaelis-Menten equation in GraphPad Prism 7 (La Jolla, CA, USA).

Network Analysis

Network analysis was performed to identify known versican and MMP-2 binding partners in the human retina and vitreous proteome. The list of total retinal, RPE-choroid, and vitreous proteins from our previously published datasets was queried in NetworkAnalyst using the STRING 10.5 search feature with filtering for experimentally validated interactions and manual curation (confidence score cutoff of >0.9). This generated a network containing 7050 nodes (proteins) and 38,096 edges (interactions). The resulting network was visualized in Cytoscape 3.5.1 (National Institute of General Medical Sciences, Bethesda, MD, USA) and binding partners of versican and MMP-2 were selected to generate a subnetwork for further analysis.

RESULTS

Clinical Phenotypes

The proband (II:1, Figs. 2A–H) was a 44-year-old male who presented for new flashes in the left eye (OS) after slowly declining vision in both eyes (OU) for many years (Figs. 2A–H). His best corrected visual acuity (BCVA) was 20/300 in the right eye (OD) and 20/500 in OS, as measured by Snellen. There was vitreous matrix degeneration, a far peripheral tractional RD in OS (Figs. 3A, 3B), and fibrosis over the anterior peripheral retina and thin epiretinal membranes in the macula. There was no anterior chamber or vitreous cell/flare noted on clinical examination. Goldmann visual fields showed ring scotomas with foveal sparing. Since age 19, he exhibited areas of extensive sheathing of the major arcade vessels, midperipheral atrophy of the retinal pigment epithelium (RPE), and pigment clumping with drusen-like deposits within the macula OU. A full body bone scan did not reveal any skeletal abnormalities, and ERG testing showed decreased scotopic and photopic responses OU. By age 32, the patient developed visually significant cataracts and underwent uneventful phacoemulsification with intraocular lens insertion OU.

The symptomatic peripheral tractional RD OS was an indication for surgery. Meticulous scleral depressed fundus exam showed vitreous bands and tractional membranes over the peripheral retina and vitreous base with a superior-nasal tractional RD; however, similar to his mother (discussed below), a retinal tear (RT) was not identified. Thus, he was treated with primary placement of a circumferential #42 scleral buckle secured with a #70 sleeve and indirect laser demarcation. Postoperatively, the RD receded, and the retina remained attached at the 1-year follow-up visit.

The proband’s mother (I:2, Figs. 2I–L) was a 65-year-old female who initially presented at age 29 with a chronic appearing inferior peripheral RD OS (Figs. 2I, 3C). Three years later she was found to have asymptomatic superior temporal subretinal fluid in OD without an identifiable RT along with the presence of visually significant cataracts OU. By age 34, she underwent lensectomy with combined scleral buckle and pars plana vitrectomy (PPV) OU. She remained aphakic OU, and her BCVA was measured to be 20/20 OD and 20/25 OS; however, this declined to 20/200 OD and 20/500 OS over the next 3
decades with peripheral pigmentary degeneration and the appearance of mild vitreous cell. Goldmann visual fields showed dense ring scotomas with mild foveal sparing. Her retinas remained attached OU.

A 39-year-old male sibling (II:2, Figs. 2M–Q) had an extensive ophthalmic surgical history beginning at age 7 when he presented with a superior bullous RD OS from a single superior RT (Fig. 3D). After multiple interventions, including placement of a scleral buckle, cryoretinopexy, PPV, and the use of intraocular gas, the retina developed proliferative vitreoretinopathy (PVR) that led to multiple re-detachments of the retina and unsuccessful surgical intervention. Ultimately, observation was elected due to poor visual prognosis, and by age 19, his BCVA in the OS deteriorated to no light perception (NLP). Over the next 2 decades, the vision in OD eventually degraded to LP due to significant pigmentary degeneration of the retina with progressive retinal atrophy over decades. Goldmann visual field showed a ring scotoma with foveal sparing. Eventually, the OS became more painful with the development of mild vitreous inflammatory cells, and at age 40 the patient underwent OS enucleation.

**Histopathology**

The eye (II:2) specimen was sent for histopathologic analysis (Fig. 4). Evaluation of the cornea revealed a degenerative pannus with band keratopathy. Centrally, there was an absence of Descemet membrane along with diffuse endothelial cell loss and secondary stromal edema. Furthermore, a diffuse dystrophic calcification on the posterior surface of the Descemet membrane was noted along with neovascularization of the angle causing subsequent closure and flattening of the anterior chamber. Focal ossification of the anterior chamber and signs of chronic iritis were likely due to multiple prior surgeries. Posteriorly, an exudative and tractional total RD with severe retinal atrophy and gliosis was present. The retinal vasculature...
demonstrated hyalinization, and occasional cystoid spaces and subretinal ossification were observed throughout. There was migration of the RPE into the neurosensory retina, often surrounding areas of retinal vasculature, with osseous metaplasia of the RPE and severe optic nerve atrophy. The RPE was atrophic and the sclera demonstrated a large cystoid space in the region of the equator consistent with the presence of a scleral buckle. These findings, along with the familial presentation of tractional RD, peripheral RPE changes, vitreous bands, and retinal atrophy observed in the other family members were highly suspicious for an inherited vitreoretinal degenerative process.

Genetic Analysis Reveals Mutation in the VCAN Gene

The clinical findings were consistent with EVR, thus family members underwent genetic analysis.\textsuperscript{13} Sanger sequencing of the VCAN coding sequence was performed, and a heterozygous adenine to guanine variant (c.4004-2A>G) within intron 7 was found in all affected members (Fig. 5A). The unaffected father did not harbor this variant. The mutation was found to disrupt the canonical splice acceptor site of exon 8. An alternative splice acceptor site is situated 39-bp downstream, which elsewhere was shown to result in a 39-bp deletion in transcripts V0 and V1.\textsuperscript{9} To understand how this genetic mutation affects protein function and pathophysiology, proteomic and structural modeling analysis were conducted.

VCAN Expression in the Human Eye Correlates With VVR Clinical Pathology

Within the human eye, versican expression has been previously reported in the cornea,\textsuperscript{36} RPE, Bruch’s membrane, choroid, sclera,\textsuperscript{37} ciliary body, and the vitreous humor.\textsuperscript{38} Transcriptome analysis of human ocular tissues by other groups have further detected VCAN RNA in the adult and fetal cornea, ciliary body, and trabecular meshwork (Table 1).\textsuperscript{39,40} We queried our human vitreous and retina proteomics datasets for further analysis.\textsuperscript{27,41,42} Versican protein expression was abundant in the vitreous (with highest expression in the vitreous core), RPE-choroid complex, and peripheral retina; however, it was absent within the juxtamacular and foveomacular regions (Table 1).\textsuperscript{42} These protein expression patterns corresponded to significant peripheral retinal pathology findings we observed in our family members, including peripheral tractional RDs and pigmentary degeneration with foveal sparing. Although abundant levels of versican protein were detected in the human vitreous proteome, the resolution was not sufficient to discern proteolytic cleavage products.
Versican contains two globular domains, G1 and G3, at the N- and C-terminals, respectively, and two chondroitin sulfate attachment domains centrally (GAG\(\alpha\) and GAG\(\beta\); Fig. 5B). The N- and C-terminal regions possess multiple motifs that can interact with diverse ECM and cell surface molecules.\(^{43,44}\) Versican contributes to the overall vitreous structure likely by linking the hyaluronan network to other proteins via its N- and C-terminal domains.\(^{45,46}\) The clinical phenotypes of our VVR patients indicated an underlying dysregulation of vitreous matrix structure. While previous studies have shown that VCAN splice mutations lead to deletions affecting exon 8, little is known about the protein structural effects of GAG\(\beta\) chain truncation or deletion.\(^1,4\)

We have previously reported that detailed protein structural analysis can provide mechanistic insight into exon mutation function and pathophysiology.\(^{47–52}\) The 39-bp deletion in our patients caused by the c.4004-2 A\(\rightarrow\)G mutation corresponded to 13 amino acids at the beginning of the versican GAG\(\beta\) chain (termed VCAN p.1335–1347; NP_004376.2; Fig. 5B). Multiple sequence alignment comparisons of these 13 residues with other species revealed that this region is conserved among mammals (Supplementary Fig. S1A), suggesting that deletion would not be well-tolerated. Thus, we considered potential consequences of deleting the VCAN p.1335–1347 region on protein structure and function.
FIGURE 5. MMP-2 cleaves the p.1335-1347 region of versican. Graphic representation of human VCAN gene exon structure showing location of the c.4004-2A>G splice site mutation in intron 7. The c.4004-2A>G creates a cryptic splice acceptor site 39-bp into exon 8 (A). Graphic representation of human versican domains (B). The VCAN p.1335-1347 region is deleted by the splice variant c.4004-2A>G. This region corresponds to a putative MMP-2 cleavage site predicted by CleavPredict. In silico docking of VCAN p.1335-1344 to the MMP-2 catalytic domain structure (PDB: 1QIB) yielded a ΔG of 6.35 ± 0.28 kcal/mol across 25 runs in AutoDock VINA (C). Surface representation of the VCAN p.1335-1344-MMP-2 complex (D). Recombinant MMP-2 proteolytic activity was measured by cleavage of a FRET-tagged substrate (VCAN p.1335-1347; 5-FAM-GRMSDLSMIGHPI-QXL; Supplementary Table S3). Results are displayed as nanomolar product formed per minute time (E). Varying concentrations of substrate (to 20 μM) were added to calculate kinetic parameters. The initial velocity (nM 5-FAM/s) of the reaction at each substrate concentration was fit to the Michaelis-Menten equation and kinetic parameters were calculated: $K_{cat} = 7.25 \times 10^{-2} \pm 4.08 \times 10^{-3}$ s$^{-1}$, $K_m = 3.31 \pm 0.65$ μM, $V_{max}$ (nM/s) = 0.5 nM/s (F).
3.31 Kcat/Km,M vitreous proteome27 and is known to cleave versican, but our mol; Figs. 5C, 5D).31 MMP-2 is highly represented in the human yielded a positive binding energy across 25 runs, further Supplementary Table S1). In silico docking of VCAN p.1335- b yt h es p l i c es i t em u t a t i o n( G R M S D — L S M I G ;F i g .4 B ; cleavage site that fell within the 13-amino acid region deleted the VCAN p.1335-1347 region contained a putative MMP-2 hydrolysis by MMP-2 (S1D, S1E). The kinetic parameters of VCAN p.1335-1347 negative control exhibited no change (Supplementary Figs. 13,27). We therefore analyzed the versican primary sequence using CleavPredict, a software program that predicts MMP substrate cleavage sites based on position weighted matrices.29 This analysis predicted the VCAN p.1335-1347 region contained a putative MMP-2 cleavage site that fell within the 13-amino acid region deleted by the splice site mutation (GRMSD—LSMIG; Fig. 4B; Supplementary Table S1). In silico docking of VCAN p.1335-1347 to the MMP-2 catalytic domain structure (PDB: 1Q1B) yielded a positive binding energy across 25 runs, further supporting it as a MMP-2 cleavage site (DG = 6.53 ± 0.28 kcal/mol; Figs. 5C, 5D).31 MMP-2 is highly represented in the human vitreous proteome27 and is known to cleave versican, but our analysis is the first to identify a specific MMP-2 cleavage site.17,27 We validated this putative MMP cleavage site by performing a fluorogenic activity assay.53 FRET peptides containing 5-FAM/ QXL dye/quencher pairs were designed around VCAN p.1335-1347 (Supplementary Table S2). Purified recombinant pro-MMP-2 was activated by incubation with APMA prior to the reaction, and MMP-2 activity was confirmed using a sensitive MMP FRET substrate, QXL-PLGC(Me)HAr-K(5-FAM), and a scrambled negative control (Supplementary Figs. S1B, S1C; Supplementary Table S2).53,54 Next, the VCAN p.1335-1347 FRET substrate and a scrambled version of its sequence were incubated with active MMP-2. Addition of the enzyme resulted in a significant increase in fluorescence, while the scrambled negative control exhibited no change (Supplementary Figs. S1D, S1E). The kinetic parameters of VCAN p.1335-1347 hydrolysis by MMP-2 (Kcat = 7.25 × 10−2 ± 4.08 × 10−3 s−1, Km = 3.31 ± 0.65 μM; Table 2) confirm that the c.4004+2A>G variant disrupts an MMP cleavage site at the beginning of the versican GAGβ domain (Figs. 5D, 5E), lending further support to our earlier finding.

We similarly tested VCAN p.1335-1347 hydrolysis by recombinant human MMP-9 catalytic domain (residues 112-445; AnaSpec) to evaluate if this site demonstrated any preference for MMP-2. Consistent with previous observations that gelatinases (MMP-2 and -9) cleave versican, recombinant MMP-9 hydrolyzed VCAN p.1335-1347 in our FRET assay (Kcat = 3.83 × 10−2 ± 6.03 × 10−3 s−1, Km = 4.43 ± 2.18 μM; Table 2). However, its catalytic efficiency was less than half that of MMP-2, suggesting that this reaction is more favorable for MMP-2 (Table 2). Disruption of this cleavage site globally changes the versican protein structure and may result in the pathophysiology underlying the clinical findings observed in our VVR patients.

Network Analysis Model

Protein–protein interactions between normally processed versican and other nonstructural proteins within the vitreous could be disrupted by the c.4004+2A>G mutation to the GAGβ domain. Polysaccharide-bound GAG chains contain negative charges that facilitate interactions with positively charged molecules (e.g., growth factors, chemokines, and cytokines).55 Dysfunction may impact overall vitreoretinal health through mis-sequestration of these proteins,56 but this process has previously been difficult to model. We performed network analysis of the human vitreous and retinal proteome to generate a model of proteins that can interact with versican.28 This analysis generated a network containing 7050 nodes (proteins) and 38,096 edges (interactions). Binding partners of versican and MMP-2 were extracted to generate a subnetwork with 28 nodes and 32 edges (Fig. 6).

Deleterious structural consequences on ECM proteins within the vitreous could account for key clinical features.57 There were seven versican-associated ECM proteins in this network, including FBLN1, FBNL2, fibulin-1 (FBN1), tenasin-C (TNR), glypican-1 (GPCI), biglycan (BGN), and aggrecan (ACAN). Organization of these proteins in the vitreous could be affected by abnormal vitreous matrix modeling. Alterations of ECM modeling proteins, including TNR and ACAN, have been observed in animal models of neurodegeneration and retinal ischemia.58 Retina ischemia can cause retinovascular leakage, which is a precursor to PVR, a key feature of our VVR patients.

Members of our VVR family and other individuals with this disease have shown findings of mild uveitis.6 We identified CXCL12, a known chemoattractant for T cells and monocytes.59 Unregulated CXCL12 activity after disruption of versican interaction could trigger inflammatory cell migration into the vitreous and promote a proinflammatory state. We also identified VEGFA, which is associated with pathologic retinal vascular permeability and PVR that can lead to RD.60–62 Proteolytic degradation of versican in vascular basement membranes has been previously shown to initiate VEGFA-

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Human MMP-2</th>
<th>Human MMP-9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kcat, s−1</td>
<td>7.25 × 10−2</td>
<td>3.83 × 10−2</td>
</tr>
<tr>
<td>± 4.08 × 10−3</td>
<td>± 6.03 × 10−3</td>
<td></td>
</tr>
<tr>
<td>Km, μM</td>
<td>3.31 ± 0.65</td>
<td>4.43 ± 2.18</td>
</tr>
<tr>
<td>Kcat/Km, M−1s−1</td>
<td>2.19 × 104</td>
<td>8.65 × 103</td>
</tr>
<tr>
<td>Relative catalytic efficiency</td>
<td>1</td>
<td>0.39</td>
</tr>
</tbody>
</table>
induced angiogenesis and vascular leakage. These putative binding partners support the hypothesis that dysregulation of matrix structure in the vitreous may result in the release of sequestered proteins and have pathologic consequences leading to the clinical features of VVR (Fig. 6).

**DISCUSSION**

Versican is a large chondroitin sulfate proteoglycan that is variably expressed in numerous types of human tissues. Previously, it was shown to function in numerous roles, such as promoting cellular adhesion, migration, proliferation, angiogenesis, and inflammation. Upregulation of versican has been implicated in malignant cancerous phenotypes, such as lymphoid and myeloid cell invasion and metastasis. Other studies have shown that versican is expressed in numerous ocular tissues, including the ciliary body (Table 1), where cleavage products of the protein are believed to constitute the versican residues that are active within the vitreous. In a previous study by Passi et al., versican was incubated with recombinant MMP-2 and MMP-9 and proteolysis was monitored by size-exclusion chromatography. The versican fragments detected by these experiments and their respective molecular weights were not described further. Through protein modeling of the VCAN mutation found within our VVR family, we are the first to show an MMP cleavage site within the GAG chain of versican that could lead to abnormalities in both matrix modeling as well as interactions with other proteins, ultimately leading to the disease phenotype.

VVR mutations commonly result in defective VCAN splicing that results in a partial or full deletion of exon 8, as well as imbalanced levels of versican isoforms (decrease V0/V1 and increase V2/V3 transcript levels). The pedigree described in the current study harbors the canonical VCAN splice site mutation (c.4004-2A>G) that introduces a cryptic splice acceptor site in intron 7 resulting in a 39-bp deletion in exon 8 that removes 13 amino acids from the GAG chain. Either a haplo-insufficiency of V0 and/or V1 or an imbalance of VCAN isoforms comprises a common pathogenic mechanism of VVR mutations known to date; however, the functional consequences of a truncated or deleted exon 8 on versican protein function are poorly understood. We investigated this question further using structural bioinformatic methodologies and identified a novel MMP proteolytic site (VCAN p.1335-1347; NP_004376.2) that is deleted as a result of this canonical splice
mutation. Removal of this MMP site may have important implications on the proteolytic processing of versican and its interactions with binding partners in the vitreous. Taken together, these findings may represent overlapping pathophysiologic mechanisms contributing to the VVR clinical phenotype (Fig. 7).

It remains unclear why the VVR disease phenotype is restricted exclusively to ocular tissues. One possibility is that the V0 and V1 transcripts affected by VVR mutations are more abundant in the eye. Studies have shown that VCAN exon 8 splice site variants lead to an imbalance of mRNA isoforms in VVR patients. Each VCAN transcript may play a unique role in the eye, and disruption of V0 and V1 may not be easily compensated by increased V2 and V3 expression. Alternatively, it is possible that while versican is critical for the normal embryologic development of the eye, it may be less essential for the development of extraocular tissues.

The absence or truncation of the GAGβ domain may have deleterious effects on VCAN protein function, among which are its interaction with other proteins within the posterior segment. Our network analysis modeling identified numerous nonstructural vitreous proteins whose interactions with normal versican may be disrupted. Of note, FBLN-1 has been known to bind versican to form a major hyaluronan-binding complex that generates cleavage products that are indispensable for the physiologic properties of the vitreous, and disruption of this interaction may underlie the pathophysiology of RD observed in both VVR and Marfan syndrome, a genetic disease due to FBLN-1 dysfunction. The network modeling analysis also identified CXCL12 and VEGFA as interacting with versican. CXCL12 is a proinflammatory chemotactic molecule that, when not sequestered by functional versican, can lead to ocular inflammation and uveitis. VEGFA is a growth factor, which is involved in increasing neovascularization, vascular permeability, and PVR formation. These characteristics have all been observed within the members of our VVR family.

There are limitations to the current study. While highly informative, in vitro assays may not reflect the full-length versican protein and physiologic conditions. Future studies are needed to validate VCAN as a physiologic MMP cleavage site in the vitreous. Although the canonical VCAN splice site mutation is associated with 39-bp deletion in exon 8, we did not perform qRT-PCR analysis of the 39-bp deletion on full blood RNA from our patients to estimate the contribution of this mutant mRNA compared with other mRNA transcripts. Finally, further in vivo studies are necessary to elucidate the downstream molecular pathways activated by the dysregulation of each of these proteins. Therapeutic targeting of these pathways may offer novel methods to mitigate disease.

**Acknowledgments**

The authors thank Leela Mahajan for surgical drawings, Vishal Perera and Jing Yang for technical assistance, and Nasreen Syed for sharing pathology reports.

Supported by National Institutes of Health (Bethesda, MD, USA) Grants K08EY020530, R01EY024665, R01EY025225, R01EY024698, R21AG050457, P50EY026877 (VBM), Doris Duke Charitable Foundation Grant No. 2013103 (Sanford Burnham Medical Research Institute, La Jolla, CA, USA), Research to Prevent Blindness (New York, NY, USA), and the Stanford ChEMH Testing Molecular Hypotheses in Human Subjects Seed Grant (Palo Alto, CA, USA). The Barbara & Donald Jonas Laboratory of Regenerative Medicine and Bernard & Shirlee Brown Glaucoma Laboratory are supported by the Congressionally Directed Medical Research Programs TSCRP:TS080017 (Fort Detrick, MD, USA), National Institute of Health (5P30EY019007, R01EY018213, R01EY024698, R01EY026682, R21AG050437); National Cancer Institute Core (5P30CA016666; Bethesda, MD, USA); the Research to Prevent
Blindness Physician-Scientist Award; unrestricted funds from Research to Prevent Blindness; the Tistou and Charlotte Kerstan Foundation (Tübingen, Germany); the Crowley Family Fund (Dallas, TX, USA); the Schneeweis Stem Cell Fund (Columbia University, New York, NY, USA); New York State (C029572, Albany, NY, USA); and the Gebroe Family Foundation (Albany, NY, USA). GV is supported by NIH grants (F30EYE027986 and T32GM007337).

Disclosure: P.H. Tang, None; G. Velez, None; S.H. Tsang, None; A.G. Bassuk, None; V.B. Mahajan, None.

References


